加载中
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
收盘时
US$1.51
+US$0.02 · +1.34%
盘后
US$1.48
−US$0.03 · -1.99%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
日内区间
当前US$1.51
52周区间
当前US$1.51
盘中时间采用ET。市场数据可能有所延迟。
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
日内区间
当前US$1.51
52周区间
当前US$1.51
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 3759.2万 USD | 4183.8万 USD | 4371.7万 USD | 3791.6万 USD | 3298.4万 USD |
| 销售、一般及管理费用 | 1381.6万 USD | 1103.9万 USD | 1204.6万 USD | 1307万 USD | 901.8万 USD |
| 营业费用 | 5140.8万 USD | 5287.7万 USD | 5576.3万 USD | 5098.6万 USD | 4200.2万 USD |
| 利息收入 | 467.8万 USD | 732万 USD | 651.9万 USD | 94.7万 USD | 2.6万 USD |
| 利息支出 | — | — | 96.4万 USD | — | — |
| 营业利润 | −5140.8万 USD | −5287.7万 USD | −5576.3万 USD | −5098.6万 USD | −4200.2万 USD |
| 净利润 | −4637.7万 USD | −4300.2万 USD | −4750.5万 USD | −4797.8万 USD | −3790.9万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$11.00
上涨空间 628.48%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2015年10月7日 | 1:4 | — | — |
已生效 2015年10月7日
1:4
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI819.12万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM365.17万0.00%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF302.91万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO148.21万0.01%180亿 USD0.06%US$112.27-0.35%
iShares Biotechnology ETFIBB103.49万0.01%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Health Care ETFVHT75.72万0.00%220亿 USD0.09%US$320.67+0.52%
Schwab U.S. Small-Cap ETFSCHA73.06万0.00%218.24亿 USD0.03%US$32.66-0.40%
iShares Micro-Cap ETFIWC43.07万0.03%13.17亿 USD0.60%US$181.66-0.73%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBVanguard Health Care ETFVHTSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
